Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KLNDW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2024181570A1 ADC5
|
|||||
| Synonyms |
WO2024181570A1 ADC5
Click to Show/Hide
|
|||||
| Organization |
TAIHO PHARMACEUTICAL CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Antibody 1
|
Antibody Info | ||||
| Antigen Name |
Syndecan-1 (SDC1)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Deruxtecan
|
|||||
ADC-specific functional property(2027 Update)
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 2016 ng/mL | Negative CD138 expression (CD138-) | ||
| Method Description |
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 10000 ng/mL | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||